Clinical trials
Atrophy clinical trials
Below are recruiting atrophy clinical trials, each written for real people, not researchers. We’re tracking 267 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06726746Recruiting
Laser treatment for vaginal dryness after menopause
This study tests if a fractional CO2 laser can safely improve vaginal atrophy symptoms like dryness, irritation, or pain during sex in postmenopausal women. It offers a non-hormonal option for those who haven't used hormone therapy or vaginal products recently.
CairoAges 45–65 - NCT05335317Recruiting
Low-intensity laser for vaginal thinning and irritation
This trial studies whether a low-intensity nanosecond laser can improve vaginal atrophy (vaginal thinning) and related symptoms. It may help reduce discomfort for people who fit the study conditions and can complete the required visits and procedures.
Nizhny NovgorodAges 40–75 - NCT07556406Recruiting
Eye imaging study for age-related macular degeneration
This study uses specialized eye imaging to track changes in geographic atrophy, a type of vision loss from macular degeneration. Researchers will use new imaging techniques to better understand how this condition progresses and how treatments work.
San Francisco, CaliforniaAges 55 years+ - NCT07554924RecruitingPhase 1/Phase 2
Gene therapy for newly diagnosed spinal muscular atrophy type I infants
This study tests SKG0201, a new gene therapy designed to treat spinal muscular atrophy type I (SMA type I), a rare genetic condition affecting muscle strength. The trial enrolls very young infants diagnosed with SMA type I to see if the treatment is safe and helps improve muscle function.
Beijing, Beijing MunicipalityAges Up to 6 months - NCT07543003Recruiting
Wearable Monitoring for Young Children With Spinal Muscular Atrophy
This study uses wearable devices (like smartwatches or activity trackers) to monitor movement and motor development in young children with spinal muscular atrophy (SMA), a rare genetic condition affecting muscle strength. The goal is to see if wearables can track disease progression and treatment response better than traditional clinic visits.
OxfordAges Up to 4 years - NCT07531719Recruiting
Risdiplam treatment study for type I and II spinal muscle atrophy
This study follows children with spinal muscular atrophy (SMA)—a genetic condition causing muscle weakness—who are being treated with a medicine called risdiplam. Researchers want to understand how well the treatment works and how it affects daily life in young patients.
CairoAges Up to 5 years - NCT07531927Recruiting
Electrical Stimulation for Geographic Atrophy Vision Loss
This study tests whether gentle electrical stimulation applied to the eye can help slow vision loss from geographic atrophy, a common cause of blindness in older adults. The treatment uses a special device to stimulate the retina (the light-sensing tissue in the back of your eye).
HamburgAges 60 years+ - NCT07514923RecruitingEarly Phase 1
ALT001 safety study for cerebellar multiple system atrophy
This early-stage trial tests a new biologic treatment called ALT001 in people with multiple system atrophy-cerebellar type (MSA-C), a rare neurological condition affecting balance and coordination. The study focuses on whether ALT001 is safe and whether it shows early signs of helping slow disease progression.
Beijing, Beijing MunicipalityAges 30–75 - NCT06019637Recruiting
Long-term safety study of Zolgensma for spinal muscular atrophy
This study follows the long-term safety of Zolgensma gene therapy in Brazilian children with spinal muscular atrophy (SMA). It helps doctors understand how safe the treatment is over time.
Curitiba, ParanáAges birth–100 years - NCT07476352RecruitingEarly Phase 1
Testing ALT001 for Multiple System Atrophy
This early-phase trial tests a new drug called ALT001 for people with multiple system atrophy (MSA). It aims to see if the drug is safe and may help slow the disease.
Beijing, Beijing MunicipalityAges 30–75 - NCT07478172Recruiting
Electrical muscle stimulation exercise for neuromuscular disease
This study tests whether whole-body electrical muscle stimulation (using small electrodes on the skin) can help adults with certain neuromuscular diseases exercise and improve muscle strength. It may be an option if you can stand for about 15 minutes at a time and have some muscle strength left.
Columbia, MissouriAges 18 years+ - NCT07467187Recruiting
Home Ventilation with Tracheostomy in Denmark (2016–2025)
This study looks at people in Denmark who need a home ventilator through a tracheostomy. It aims to understand their care and outcomes over several years.
CopenhagenAges Any age - NCT07446894RecruitingPhase 3
Testing MSA-01 for multiple system atrophy
This phase 3 trial tests a new oral drug (MSA-01) for people with multiple system atrophy. It aims to see if the drug can slow disease progression and improve daily function.
Nagoya, Aichi-kenAges 30–79 - NCT07448610RecruitingPhase 4
Real-world safety and effectiveness of gene therapy for spinal muscular atrophy
This study tracks how well the gene therapy ITVISMA works in everyday medical practice for people with spinal muscular atrophy (SMA). It aims to see if the treatment is safe and effective in a real-world setting.
New York, New YorkAges 2–100 - NCT04174157Recruiting
Spinal muscular atrophy patient registry for OAV-101
This is a registry that collects information from people with spinal muscular atrophy (SMA) who have been treated with OAV-101. It helps researchers understand how patients do over time after this treatment.
Phoenix, ArizonaAges Any age - NCT07444476RecruitingPhase 3
Study of salanersen for spinal muscular atrophy (ages 15-60)
This trial tests a medicine called salanersen (BIIB115) to see how well it improves movement and how safe it is in people with spinal muscular atrophy (SMA). It includes those who have never taken an SMA drug or are currently on risdiplam and willing to switch.
Palo Alto, CaliforniaAges 15–60 - NCT07441642RecruitingPhase 2
Study of FWY003 for geographic atrophy in age-related macular degeneration
This trial tests an investigational drug FWY003 against a placebo to see if it can slow or stop the progression of geographic atrophy, a form of advanced age-related macular degeneration that causes vision loss.
Huntington Beach, CaliforniaAges 50 years+ - NCT06072105Recruiting
Medical decisions in multiple system atrophy: a study in Austria
This study looks at how medical decisions are made for people with multiple system atrophy (MSA). It includes both people with MSA and their unpaid caregivers who live in Austria and speak German. Participants and caregivers will share their experiences through online interviews to help improve future care.
Innsbruck, AustriaAges 30 years+ - NCT07400198Recruiting
Walking and Bone Health Study for SMA
This study looks at walking and bone health in people with spinal muscular atrophy (SMA). It helps researchers understand how SMA affects your gait (the way you walk) and your bones, which could lead to better treatments.
New York, New YorkAges 8–50 - NCT07392255RecruitingPhase 1/Phase 2
Testing CTx001 for geographic atrophy (GA) in AMD
This trial is testing a new treatment called CTx001 for people with geographic atrophy (GA), a late stage of dry age-related macular degeneration (AMD). The goal is to see if the treatment is safe and can slow vision loss.
Carmel, IndianaAges 55 years+ - NCT06831214Recruiting
Bone growth with collagen membrane graft for jaw atrophy
This trial studies a new technique to help build up bone in the upper jaw (maxilla) that has become thin. It uses a special membrane and graft material to encourage bone growth, which may help people who need dental implants.
CairoAges 18–60 - NCT07332702Recruiting
Spinal muscular atrophy gene study
This study looks at changes in two genes, SMN1 and SMN2, which are linked to spinal muscular atrophy (SMA). It aims to better understand the different versions of these genes in healthy people and those with SMA. Participating involves a blood sample and genetic analysis.
RouenAges 18 years+ - NCT03761446Recruiting
Testing how diabetes affects muscle loss after bed rest
This study looks at how pre-diabetes or type 2 diabetes may change skeletal muscle loss and recovery in older adults after a period of bed rest. It may help researchers understand why recovery can be slower and how to better protect muscle in people as they age.
Orlando, FloridaAges 60–80 - NCT07289477RecruitingPhase 1
Study of NouvNeu001 for Multiple System Atrophy
This study tests a new injection called NouvNeu001 for people with Multiple System Atrophy (MSA). The goal is to see if it can help control symptoms that standard treatments aren't managing well.
Beijing, Beijing MunicipalityAges 30–70
Hear when a new Atrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for atrophy?
- Yes. Clin2 currently lists 267 recruiting atrophy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a atrophy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a atrophy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.